Category: Funding Roundup
Hitachi Aloka Medical and Omega Medical Imaging land a collective $28.4 million in contracts to provide military and federal civilian agencies with radiology products, services and supplies.
The U.S. Department of Defense awarded contract extensions worth a total $28.4 million to Hitachi's (NYSE:HIT) Aloka Medical and to Omega Medical, according to a federal memo.
Respiratory Motion is more than halfway through an $8.8 million Series B funding round, along the way touting positive findings from a trial of its ExSpiron ventilation monitor.
Respiratory Motion is on a roll, landing nearly $6 million in new funding and unveiling positive results from a clinical study of its ExSpiron non-invasive respiratory monitor.
The Waltham, Mass.-based hopes to close the Series B round with $8.8 million, having raised $5.8 million so far from lead investor Easton Capital and other existing investors. The funds are slated to support sales and marketing efforts for the ExSpiron system, the company said.
Lumicell amends its $1 million equity and Series B preferred funding round after raising nearly $600,000 from an additional 2 investors.
Imaging systems maker Lumicell Diagnostics amended a previously closed $1 million funding round after landing another $560,000 in financing from 2 new investors, regulatory filings show.
Invuity Inc. raises $36 million in support of its surgical lighting technologies, which promise to "dramatically improve" visibility in minimally invasive surgeries.
San Francisco surgical lighting company Invuity Inc. secured $36 million in a Series E funding round, planning on using the new cash to "accelerate commercial initiatives."
Stealthy BioTrace Medical brings in $3.4 million in a hoped-for $3.5 million round for the heart pacing technology it's developing.
BioTrace Medical is closing in on its $3.5 million goal, having raised $3.4 million in a funding round, according to a regulatory filing.
BioTrace, which is backed by early-stage medtech angel Xandex Investments, is developing a temporary cardiac pacing device to treat reversible symptomatic bradycardia.
Bruin Biometrics secured $10 million for its wound, joint and implant scanning devices in a funding round that was oversubscribed by nearly 37%.
Bruin Biometrics said it closed an oversubscribed funding round that beat its target by nearly $2.7 million.
The Los Angeles-based company, which makes biometric sensors designed to detect tissue damage in wounds, joints and orthopedic implants, said the $10 million round came in well aboce its goal.
NxThera puts a bow on a $20 million Series C round for its Rezūm prostate device.
NxThera said it closed a $20 million Series C round that topped its initial $18 million target.
Maple Grove, Minn.-based NxThera won CE Mark approval in the European Union last August for its Rezūm prostate device, which uses steam to reduce the size of the prostate to relieve urinary symptoms from benign prostate hyperplasia.